Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 160 in metastatic castration-resistant prostate cancer
NL-OMON52552Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of acapatamab and pembrolizumab in prostate cancer (PCa) (8 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 2 more. Started Dec 2019; status: completed.
02
Drugs
acapatamabpembrolizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52552.